Apellis Pharmaceuticals Inc (APLS)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Apellis Pharmaceuticals Inc chart...

About the Company

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

CEO

Cedric Francois

Exchange

NASDAQ

Website

http://apellis.com/

$809M

Total Revenue

794

Employees

$7B

Market Capitalization

-11.78

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $APLS News

Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?

5h ago, source:

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals

1d ago, source:

Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $79.4, a high estimate ...

Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?

16d ago, source: American Association of Individual Investors

Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...

Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ...

8d ago, source:

Mark Delong, Chief Business & Strategy Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), has sold 9,913 shares of the ...

Apellis Pharmaceuticals Inc APLS

8d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Business Insider

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2023 financial results and business highlights.

Apellis Pharmaceuticals, Inc. (APLS) Q4 and Full Year 2023 Earnings Call Transcript

1mon ago, source: Seeking Alpha

Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen ...

Apellis Pharmaceuticals Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...